LEADS BIOLABS-B (09887.HK): Chairman Plans HKD 20M H-Share Purchase
NewTimeSpace News: On 19 November 2026, Nanjing Leads Biolabs Co., Ltd. (stock code: 9887) announced on a voluntary basis that chairman, executive director and chief executive Dr Kang Xiaoqiang, citing recognition of the company's value and confidence in its future business development and growth potential, plans to purchase the company's H shares on the open market using his own funds or those of his close associates over about six months from the date of the announcement. The total consideration is expected not to exceed HKD 20 million, subject to the Listing Rules and other applicable laws.
As at the date of the announcement, Dr Kang was interested or deemed interested in a total of 29,500,320 H shares, representing about 14.92% of the issued H shares and about 14.83% of the company's total issued share capital. The company said that, based on available information and to the knowledge and belief of the directors, it will maintain sufficient public float in the issued H shares even if the plan is fully implemented.
The board considers the plan reflects Dr Kang's firm confidence in the company's value and long-term prospects. The company cautioned that, given future capital market changes and unforeseen factors, the plan may or may not be fully implemented, and advised shareholders and potential investors to exercise caution.
- LEADS BIOLABS-B (09887.HK): Presents LBL-024 Data at Jefferies
- LEADS BIOLABS-B (09887.HK): LBL-047 completes first SLE patient dosing in Phase I Part B
- LEADS BIOLABS-B (09887.HK): LBL-024 data presented at ESMO 2026, 3L EP-NEC median OS 8.7 months
- LEADS BIOLABS-B (09887.HK): Updated LBL-034 Data in RRMM Presented at ESMO
- LEADS BIOLABS-B (09887.HK): Six Abstracts on Weilixin and LBL-034 Published at ESMO 2026; Three Chosen for Oral Presentations